Success Metrics

Clinical Success Rate
76.8%

Based on 242 completed trials

Completion Rate
77%(242/315)
Active Trials
63(13%)
Results Posted
53%(129 trials)
Terminated
73(15%)

Phase Distribution

Ph not_applicable
48
10%
Ph phase_2
172
36%
Ph phase_3
101
21%
Ph phase_1
64
13%
Ph phase_4
68
14%
Ph early_phase_1
9
2%

Phase Distribution

73

Early Stage

172

Mid Stage

169

Late Stage

Phase Distribution462 total trials
Early Phase 1First-in-human
9(1.9%)
Phase 1Safety & dosage
64(13.9%)
Phase 2Efficacy & side effects
172(37.2%)
Phase 3Large-scale testing
101(21.9%)
Phase 4Post-market surveillance
68(14.7%)
N/ANon-phased studies
48(10.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.2%

242 of 335 finished

Non-Completion Rate

27.8%

93 ended early

Currently Active

63

trials recruiting

Total Trials

479

all time

Status Distribution
Active(73)
Completed(242)
Terminated(93)
Other(71)

Detailed Status

Completed242
Terminated73
unknown71
Recruiting41
Active, not recruiting22
Withdrawn20

Development Timeline

Analytics

Development Status

Total Trials
479
Active
63
Success Rate
76.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 19 (1.9%)
Phase 164 (13.9%)
Phase 2172 (37.2%)
Phase 3101 (21.9%)
Phase 468 (14.7%)
N/A48 (10.4%)

Trials by Status

recruiting419%
not_yet_recruiting92%
completed24251%
active_not_recruiting225%
terminated7315%
withdrawn204%
enrolling_by_invitation10%
unknown7115%

Recent Activity

Clinical Trials (479)

Showing 20 of 479 trialsScroll for more
NCT07763210Phase 2

Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma

Recruiting
NCT04629248Phase 3

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

Active Not Recruiting
NCT07852195Phase 2

Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer

Not Yet Recruiting
NCT02166463Phase 3

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Active Not Recruiting
NCT04438382Phase 2

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Terminated
NCT04544436Phase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Active Not Recruiting
NCT06717347Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Recruiting
NCT06317662Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Recruiting
NCT01790594Phase 2

Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation

Terminated
NCT01436305Phase 2

Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation

Terminated
NCT01856257Phase 2

Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen

Terminated
NCT04066114Phase 1

Treg Modulation With CD28 and IL-6 Receptor Antagonists

Completed
NCT02495077Phase 2

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

Completed
NCT07412470Phase 2

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

Recruiting
NCT03952637Phase 1

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

Recruiting
NCT04127578Phase 1

Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

Active Not Recruiting
NCT02784210Phase 2

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

Recruiting
NCT02464696Not Applicable

Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure

Recruiting
NCT04216524Phase 2

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Recruiting
NCT07803978Early Phase 1

Prospective Randomized Controlled Study: Amimaitosai Injection Combined With Corticosteroids for Gastrointestinal aGVHD

Enrolling By Invitation

Drug Details

Intervention Type
DRUG
Total Trials
479